Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.

Literature DB >> 27207612

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.

Aharon Ronson¹, Ariella Tvito¹, Jacob M Rowe^2,3.

Abstract

Patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have a dismal prognosis with less than 10 % of patients surviving 5 years. Most such patients cannot be rescued with currently available therapies, whatever the initial treatment they receive. Therefore, there is an urgent need for novel treatment options. Fortunately, over the past several years, an improved understanding of the biology of the disease has allowed the identification of rational molecular targets for therapeutic endeavors and the emergence of novel therapies has sparked great interest. This review will discuss the current treatment landscape for adult patients with relapsed and/or refractory ALL.

Entities: Disease Species

Keywords: Acute lymphoblastic leukemia; Blinatumomab; Chimeric antigen receptor-T; Relapsed/refractory

Mesh：

Substances：
Antineoplastic Agents

Year: 2016 PMID： 27207612 DOI： 10.1007/s11912-016-0519-8

Source DB: PubMed Journal: Curr Oncol Rep ISSN： 1523-3790 Impact factor: 5.075

75 in total

Review 1. Pediatric-like therapy for adults with ALL.

Authors: Hervé Dombret; Thomas Cluzeau; Françoise Huguet; Nicolas Boissel
Journal: Curr Hematol Malig Rep Date: 2014-06 Impact factor: 3.952

2. Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors: Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal: N Engl J Med Date: 2014-10-16 Impact factor: 91.245

3. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

Authors: Hagop Kantarjian; Deborah Thomas; Jeffrey Jorgensen; Elias Jabbour; Partow Kebriaei; Michael Rytting; Sergernne York; Farhad Ravandi; Monica Kwari; Stefan Faderl; Mary Beth Rios; Jorge Cortes; Luis Fayad; Robert Tarnai; Sa A Wang; Richard Champlin; Anjali Advani; Susan O'Brien
Journal: Lancet Oncol Date: 2012-02-21 Impact factor: 41.316

4. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.

Authors: L M Hinman; P R Hamann; R Wallace; A T Menendez; F E Durr; J Upeslacis
Journal: Cancer Res Date: 1993-07-15 Impact factor: 12.701

5. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.

Authors: Anjali S Advani; Shannon McDonough; Steven Coutre; Brent Wood; Jerald Radich; Martha Mims; Margaret O'Donnell; Stephanie Elkins; Michael Becker; Megan Othus; Frederick R Appelbaum
Journal: Br J Haematol Date: 2014-03-03 Impact factor: 6.998

6. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.

Authors: Xavier Thomas; Jean-Michel Boiron; Françoise Huguet; Hervé Dombret; Ken Bradstock; Norbert Vey; Tibor Kovacsovics; André Delannoy; Nathalie Fegueux; Pierre Fenaux; Aspasia Stamatoullas; Jean-Paul Vernant; Olivier Tournilhac; Agnès Buzyn; Oumedaly Reman; Christiane Charrin; Claude Boucheix; Jean Gabert; Véronique Lhéritier; Denis Fiere
Journal: J Clin Oncol Date: 2004-09-07 Impact factor: 44.544

7. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.

Authors: E Tavernier; J-M Boiron; F Huguet; K Bradstock; N Vey; T Kovacsovics; A Delannoy; N Fegueux; P Fenaux; A Stamatoullas; O Tournilhac; A Buzyn; O Reman; C Charrin; C Boucheix; J Gabert; V Lhéritier; J-P Vernant; H Dombret; X Thomas
Journal: Leukemia Date: 2007-07-05 Impact factor: 11.528

8. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

Authors: Hagop M Kantarjian; Varsha Gandhi; Peter Kozuch; Stefan Faderl; Francis Giles; Jorge Cortes; Susan O'Brien; Nuhad Ibrahim; Fadlo Khuri; Min Du; Mary Beth Rios; Sima Jeha; Peter McLaughlin; William Plunkett; Michael Keating
Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544

9. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

Authors: Hagop Kantarjian; Varsha Gandhi; Jorge Cortes; Srdan Verstovsek; Min Du; Guillermo Garcia-Manero; Francis Giles; Stefan Faderl; Susan O'Brien; Sima Jeha; Jan Davis; Zeev Shaked; Adam Craig; Michael Keating; William Plunkett; Emil J Freireich
Journal: Blood Date: 2003-06-05 Impact factor: 22.113

Review 10. Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine.

Authors: Tyler Davis; Sherif S Farag
Journal: Int J Nanomedicine Date: 2013-09-16

13 in total

1. Re-induction chemotherapy using FLAG-mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates.

Authors: Inaam Bashir Hassan; Jorgen Kristensen; Khalid Al Qawasmeh; Arif Alam
Journal: Int J Hematol Date: 2018-06-27 Impact factor: 2.490

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.

Review 1. Pediatric-like therapy for adults with ALL.

2. Chimeric antigen receptor T cells for sustained remissions in leukemia.

3. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

4. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.

5. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.

6. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.

7. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.

8. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

9. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

Review 10. Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine.

1. Re-induction chemotherapy using FLAG-mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates.

Review 2. Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.

Review 3. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.

Review 4. Structure-guided engineering of TGF-βs for the development of novel inhibitors and probing mechanism.

5. Blinatumomab-induced T cell activation at single cell transcriptome resolution.

Review 6. P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia.

Review 7. Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia.

8. Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice.

Review 9. Chimeric antigen receptor-modified T cells: CD19 and the road beyond.

10. Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells.